Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobis: Medical Cannabis for Neurodegenerative Diseases
2023-507715-35-02Phase 2Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) comparing Avextra 10/10 with Placebo oil (2 arms). Primary endpoints: Quality of life improvement (SF-36) and Safety and tolerability. Planned start Jul 2024; status: authorised.
02
Drugs
Avextra 10/10
03
Conditions
amyotrophic lateral sclerosis (ALS)Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2023-507715-35-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507715-35-02.